Searchable abstracts of presentations at key conferences in endocrinology

ea0070oc7.4 | Endocrine-related Cancer | ECE2020

Increased E2F1 mRNA and miR-17-5p expression may predict aggressiveness of pituitary neuroendocrine tumours

García-Martínez Araceli , Martínez-López Sebastián , López-Muñoz Beatriz , Cámara Rosa , Fajardo Carmen , Lamas Cristina , Silva-Ortega Sandra , Aranda Ignacio , Picó Antonio

Introduction: E2F1 regulates the expression of genes required for cell cycle progression and apoptosis. miR-17-5p regulates expression of E2F1. Both miR-17-5p and E2F1 have been described deregulated in cancer but they have been scarcely studied in human pituitary neuroendocrine tumours (PitNETs).The aim of the present study was to find biomarkers of aggressiveness in PitNETs and report the correlation between E2F1 and...

ea0070aep653 | Pituitary and Neuroendocrinology | ECE2020

Characterization of pituitary adenomas by immunohistochemistry of pituitary-specific transcription factors and their correlation with hormonal subtypes

García-Martínez Araceli , Silva-Ortega Sandra , López-Muñoz Beatriz , Moreno-Pérez Óscar , Monjas Irene , Abarca Javier , Picó Antonio , Aranda Ignacio

Introduction: The immunohistochemical characterization of Pit-1, Tpit and SF-1 transcription factors allows the identification of the three adenohypophyseal cell lines and has been incorporated into the latest WHO classification of pituitary adenomas (PA). The aim of the present study was to quantify the protein expression of pituitary-specific transcription factors (TF) by immunohistochemistry (IHC) and to correlate these results with the identification based on hormonal prot...

ea0070aep588 | Pituitary and Neuroendocrinology | ECE2020

New advances in the diagnosis of gonadotroph tumours

García-Martínez Araceli , Morote-Guillén Cristina , Martínez-López Sebastián , Eugenia Torregrosa-Quesada María , Silva-Ortega Sandra , López-Muñoz Beatriz , Moreno Óscar , Aranda Ignacio , Picó Antonio

Introduction: Gonadotroph tumours (GT) are the most common subtype of silent pituitary neuroendocrine tumours. The diagnosis of this subtype of tumours is established after surgery. There are no reliable markers of aggressiveness to predict their clinical course and, moreover, immunohistochemistry (IHC) usually classifies GT as null cell tumours. The aim of the present study was to correlate molecular, immunohistochemical and biochemical gonadotropin expression, to quantify th...